目的 探讨舒血宁对经皮冠脉介入(PCI)患者血管内皮功能及主要不良心血管事件(MACE)影响.方法 将于我院行PCI的60例患者分为观察组和对照组.对照组采用阿托伐他汀治疗,观察组在对照组基础上采用舒血宁治疗.对比两组患者的炎性因子水平、血管内皮功能及MACE发生率.结果 治疗后,两组的C反应蛋白(CRP)、白介素-6(IL-6)、内皮素(ET)、血管性血友病因子(vWF)水平均低于治疗前,且观察组CRP、IL-6、ET、vWF水平低于对照组(P＜0.05).观察组MACE发生率为6.67％,明显低于对照组的30.00％(P＜0.05).结论 舒血宁可降低PCI术后患者炎性因子水平及MACE发生率,改善血管内皮功能,值得临床推广应用.
Objective To explore the effects of Shuxuening on endothelial function and major adverse cardiovascular events(MACE)in patients with percutaneous coronary intervention(PCI).Methods 60 PCI patients in our hospital were divided into observation group and control group.The control group was treated with atorvastatin,while the observation group was treated with Shuxuening on the basis of the control group.The levels of inflammatory factors,vascular endothelial function and incidence of MACE were compared between two groups.Results After treatment,the C-reactive protein(CRP),interleukin-6(IL-6),endothelin(ET)and von Willebrand factor(vWF)levels of the two groups decreased,and the CRP,IL-6,ET and vWF levels of the observation group were lower than those of the control group(P＜0.05).The incidence of MACE in the observation group was 6.67％,significantly lower than 30.00％in the control group(P＜0.05).Conclusions Shuxuening can reduce the levels of inflammatory factors and the incidence of MACE in patients after PCI,and improve the vascular endothelial function,which is worthy of clinical promotion and application.
李纪松;梁伟;寇广亚
新乡市第二人民医院心内科,河南新乡 453000
临床医学
舒血宁;经皮冠脉介入;炎症因子;血管内皮功能;主要不良心血管事件
Shuxuening;Percutaneous coronary intervention;Inflammatory factor;Vascular endothelial function;Major adverse cardiovascular event
《临床医学工程》 2024 (005)
603-604 / 2
10.3969/j.issn.1674-4659.2024.05.0603
评论